Santhera Pharmaceuticals Holding AG: Santhera Receives US Patent for Fipamezole in the Treatment of Neurodegenerative Diseases

     Santhera Pharmaceuticals Holding AG: Santhera Receives US Patent for
          Fipamezole in the Treatment of Neurodegenerative Diseases

Santhera Pharmaceuticals Holding AG / Santhera Receives US Patent for
Fipamezole in the Treatment of Neurodegenerative Diseases . Processed and
transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely
responsible for the content of this announcement.

Liestal, Switzerland, March19, 2014 - Santhera Pharmaceuticals (SIX:SANN)
announced today that the United States Patent and Trademark Office has issued
a Notice of Allowance for a Santhera patent which protects the use of the
oromucosal administration route for fipamezole. The US patent 8,653,122, which
provides an exclusivity period until 2027, is crucial for the commercial
exploitation of fipamezole in the field of neurodegenerative diseases.
Santhera has global rights to fipamezole and has previously published
promising data of its Phase IIb clinical trial in the treatment of
levodopa-induced dyskinesia in Parkinson's disease.

The US patent claims the use of fipamezole via the oromucosal route of
administration, which is essentially the only method of administration that
achieves sufficient plasma levels of the drug and that is suitable for
long-term treatment. Santhera previously received notice of allowance for
equivalent patents in the EU and most other important markets worldwide.

Thomas Meier, Chief Executive Officer of Santhera, commented: "This US patent
now completes the patent protection estate for the fipamezole program and
allows the commercial exploitation of fipamezole as potential treatment of
neurodegenerative diseases, most notably of levodopa-induced dyskinesia in
Parkinson's disease. As Santhera is mainly focusing on the registration of
Raxone^®/Catena^® in Leber's Hereditary Optic Neuropathy, fipamezole is
currently available for licensing."

About Fipamezole
Fipamezole is an innovative and highly selective adrenergic alpha-2 receptor
antagonist, perceived by clinicians to be one of the most promising drug
candidates for the treatment of levodopa-induced dyskinesia in Parkinson's
disease, the second most common and a severely debilitating neurodegenerative
disorder. Santhera demonstrated in a Phase IIb clinical trial that oromucosal
fipamezole has the potential to safely and effectively reduce levodopa-induced
dyskinesia and daily "off" time without exacerbation of parkinsonism [1].

[1] LeWitt P., et al (2012). Randomized clinical trial of fipamezole for
dyskinesia in Parkinson disease (FJORD study). Neurology 79:163-169.

                                     ***

About Santhera
Santhera Pharmaceuticals (SIX:SANN) is a Swiss specialty pharmaceutical
company focused on the development and commercialization of innovative
pharmaceutical products for the treatment of orphan mitochondrial and
neuromuscular diseases, such as Leber's Hereditary Optic Neuropathy, Duchenne
Muscular Dystrophy and primary progressive Multiple Sclerosis, all of them
areas of high unmet medical need with no current therapies.
For further information, please visit www.santhera.com.



Raxone^® and Catena^®are trademarks of Santhera Pharmaceuticals.





For further information, contact
Thomas Meier, Chief Executive Officer
Phone: +41 61 906 89 64
thomas.meier@santhera.com

Disclaimer / Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for
or purchase any securities of Santhera Pharmaceuticals Holding AG. This
publication may contain certain forward-looking statements concerning the
Company and its business. Such statements involve certain risks, uncertainties
and other factors which could cause the actual results, financial condition,
performance or achievements of the Company to be materially different from
those expressed or implied by such statements. Readers should therefore not
place undue reliance on these statements, particularly not in connection with
any contract or investment decision. The Company disclaims any obligation to
update these forward-looking statements.

News release US patent

------------------------------------------------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf
of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for
the content, accuracy and originality of the information contained therein.
Source: Santhera Pharmaceuticals Holding AG via Globenewswire
HUG#1769735

--- End of Message ---

Santhera Pharmaceuticals Holding AG
Hammerstrasse 49 Liestal Switzerland

ISIN: CH0027148649;
 
Press spacebar to pause and continue. Press esc to stop.